A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (QUATTRO)
A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer
研究概览
详细说明
This is a single-arm, multicentre phase II study evaluating the efficacy and safety of Bevacizumab (BV) in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al. ASCO2013) as first-line treatment for Japanese metastatic colorectal cancer patients.
This study is composed two steps because of collecting safety issue in Japanese patient.
As First step (Step 1), It assess on the initial safety information in ten Japanese patients of the end of 2nd cycle. it is evaluated by DMC.
In parallel with the confirmation of the initial safety issue, register up to 65 cases in total and Step 1 patient, to evaluate the efficacy and safety (Step2).
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Tokyo
-
Shinjuku、Tokyo、日本、162-0814
- EPS Corporation
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written Informed consent.
- Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.
- Not resectable metastatic colorectal cancer
- Age at enrollment is >= 20 and <= 75 years
- ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years
- One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis.
- Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.)
Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed.
Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+
- UGT1A1 genotype tested. Categorized into Wild or single Hetero.
Exclusion Criteria:
- Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field.
- Untreated brain metastases or spinal cord compression or primary brain tumors.
- History of CNS disease.[except for asymptomatic Lacunar stroke]
- Requiring chronic systemic corticosteroid treatment.
- Current or recent ongoing treatment with anticoagulants.
- Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication.
- Treatment with any investigational drug within 4 weeks.
- Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea, >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases.
- Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure.[except for implantation of central venous catheter and port system.]
- Lack of physical integrity of the upper gastrointestinal tract.
- Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males.
- Hepatitis B or hepatitis C. Evidence of HIV infection.
- Previous Chemotherapy for other organs.
- Other active co-existing malignancies.
- History / Presence of thrombosis within 1 year requiring medication.
- History / Presence of paralytic ileus, obstruction or gastrointestinal perforation.
- Malignant coelomic fluid required drainage.
- History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications.
- History of fluoropyrimidine severe side effects caused by DPD defect.
- Interstitial pneumonitis or pulmonary fibrosis.
- Evidence or requiring systemic treatment for Infectious disease.
- Patient who is judged by the investigator to be inappropriate for study participation for any reason.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:FOLFOXIRI plus bevacizumab
Induction therapy is followed by the maintenance therapy. [Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. [Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. |
鉴于IV
其他名称:
鉴于IV
其他名称:
鉴于IV
其他名称:
鉴于IV
其他名称:
鉴于IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS) at 10 months
大体时间:PFS rate at 10 months from study entry
|
PFS by investigator-reported measurements according to CT image. PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause. PD was defined as Overall Response by RECIST criteria v1.1 according to CT image. |
PFS rate at 10 months from study entry
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response rate (RR) by central review.
大体时间:Up to 18 months
|
Response evaluation was performed according to RECIST criteria v1.1.
|
Up to 18 months
|
|
Response rate (RR) by investigator-reported measurements.
大体时间:Up to 30 months
|
Response evaluation was performed according to RECIST criteria v1.1.
|
Up to 30 months
|
|
PFS by central review according to CT image.
大体时间:Up to 18 months
|
PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.
|
Up to 18 months
|
|
Overall survival (OS)
大体时间:Up to 30 months
|
OS was calculated from the day of registration in this study to death from any cause.
|
Up to 30 months
|
|
Efficacy by RAS status ; RR,PFS,OS
大体时间:Up to 30 months
|
RR,PFS,OS according to tumor RAS status.
|
Up to 30 months
|
|
Incidence of adverse events
大体时间:Up to 30 months
|
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
All adverse events was collected in duration from starting treatment to whichever shorter "after 30 days from withdrawal treatment" or "later treatment was started".
|
Up to 30 months
|
|
Time to treatment-failure
大体时间:Up to 30 months
|
Up to 30 months
|
|
|
Completion rate in Induction treatment
大体时间:Up to 30 months
|
Up to 30 months
|
|
|
Relative Dose Intensity
大体时间:Up to 30 months
|
Up to 30 months
|
|
|
Treatment duration
大体时间:Up to 30 months
|
Up to 30 months
|
合作者和调查者
调查人员
- 首席研究员:Takeshi Kato, M.D., Ph.D、Department of Surgery, National Hospital Organization Osaka National Hospital.
- 首席研究员:Akiyoshi Kanazawa, M.D., Ph.D、Department of Surgery, Shimane Prefectural Central Hospital.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- QUATTRO
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.